purdue pharma's three top executives, president michael friedman, top lawyer, howard r. udell, and former chief medical officer paul d. goldenheim, pleaded guilty as individuals to misleading the public about oxycontin's risk of addiction, a misbranding charge — a criminal violation. at their sentencing hearing in july 2007, judge james p. jones of the united states district court sentenced friedman, udell and goldenheim to three years’ probation", and community service in drug treatment programs and , and in fines, respectively, representing $34.5 million in fines.